Isomorphic Labs, a spin-out of DeepMind, has recently signed two groundbreaking deals with major pharmaceutical companies aimed at revolutionizing drug discovery using artificial intelligence (AI) technology. With the potential to receive a combined total of nearly $3 billion from these collaborations, Isomorphic Labs is poised to make significant strides in tackling various diseases and potentially reaping billions in profit.
The first partnership is with Novartis, where Isomorphic Labs will work alongside the pharma giant to identify small molecule therapeutics for three undisclosed targets. In addition to an upfront payment of $37.5 million, Isomorphic Labs is eligible to receive up to $1.2 billion in performance-based milestone payments. Fiona Marshall, Novartis President of Biomedical Research, highlighted the transformative potential of cutting-edge AI technologies like AlphaFold, expressing excitement about how they can revolutionize drug discovery and enable the development of life-changing medicines.
The second collaboration is with Eli Lilly, with a focus on discovering small molecule therapeutics against multiple targets. Isomorphic Labs will receive an upfront cash payment of $45 million and stands to gain up to $1.7 billion in performance-based milestone payments. Isomorphic Labs founder and CEO Demis Hassabis sees this partnership as an opportunity to leverage their proprietary technology platform, the next generation of AlphaFold, and powerful computing capabilities to advance Lilly’s drug development programs. Both parties share a common focus on pioneering drug design approaches and a deep appreciation for cutting-edge science.
By harnessing the power of AI, Isomorphic Labs aims to accelerate the process of drug discovery and ultimately find cures for devastating diseases. These partnerships represent an exciting step forward in revolutionizing the pharmaceutical industry by integrating advanced AI technologies with deep expertise in medicinal chemistry and disease research. With the potential for significant financial gains and the promise of delivering life-changing medicines to patients, Isomorphic Labs is poised to make a profound impact in the field of healthcare.
The source of the article is from the blog yanoticias.es